foxo4-dri human trial peptide senolytic Development of a novel senolytic by precise disruption of FOXO4 Senolytics: from pharmacological inhibitors to
Description
By selectively targeting fat cells without affecting muscle tissue, it shifts the weight loss equation toward preferential fat loss
Beta1 Integrin: critical path to antiangiogenic therapy resistance and beyond
Pickart, L., Vasquez-Soltero, J., Pickart, F., & Majnarich, J
For more information, contact us or book an appointment
